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PSORS1 is the major susceptibility locus for psoriasis vulgaris (PV) and lies within an approximately 200 kb
segment of the major histocompatibility complex on chromosome 6p21.3. Alleles of candidate genes in this region
including human leukocyte antigen (HLA)-C, a-helical coiled coil rod (HCR), and corneodesmosin (CDSN) show
association with early-onset PV. Late-onset psoriasis (LOP) is deﬁned as a disease with onset after 40 y of age and
is typically sporadic. We assessed the role of PSORS1 in genetic susceptibility to LOP. Genotyping for HLA-C
alleles and seven single nucleotide polymorphisms (SNP) within the genes HCR and CDSN was performed in LOP
(n¼ 145) and normal controls (n¼ 309). Statistical analysis of allelic frequencies included calculation of odds ratio
and v2 comparisons. LOP demonstrated only a weak association to PSORS1 alleles HLA-Cw6 (p¼ 0.037), CDSN5
(p¼ 0.041), HCRWC (p¼ 0.013), and HCR SNP þ 325 (p¼ 0.038). Patients with age of onset for psoriasis of 50 y or
above provided no evidence of association with any of these alleles. These data suggest that the study cohort may
include a number of subjects who harbor PSORS1 predisposition to early-onset psoriasis and yet do not present
with disease by the age of 40 y. Thus this study demonstrates that PSORS1 is not a major inherited risk factor in the
pathogenesis of LOP. These data suggest that the exclusion of LOP subjects from case–control studies will aid
further delineation of the PSORS1 locus. Future genome-wide studies will be required to identify loci conferring
risk for late-onset disease.
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Psoriasis is a chronic, debilitating inflammatory skin disease
affecting diverse ethnic groups with a population incidence
of 2%–3% in populations of European origin (Christophers,
2001). Genome-wide scans performed using families with
early-onset psoriasis have identified at least nine putative
psoriasis susceptibility loci (Capon et al, 2002). The major
susceptibility locus for psoriasis (PSORS1) is within the
major histocompatibility complex (MHC) on chromosome
6p21.3 (Nair et al, 1997; Trembath et al, 1997), and accounts
for approximately 35%–50% of the genetic risk for psoria-
sis. An approximately 200 kb consensus region for PSORS1
lies within the MHC class I region (Balendran et al, 1999;
Oka et al, 1999; Nair et al, 2000) and contains potential
candidate genes for psoriasis susceptibility including hu-
man leukocyte antigen (HLA)-C, a-helical coiled coil rod
(HCR), and corneodesmosin (CDSN). Specific alleles of
these genes, HLA-Cw0602, HCRWWCC, and CDSN5,
have consistently demonstrated significant association with
familial psoriasis vulgaris (PV) with each found in strong
linkage disequilibrium with each other. We recently demon-
strated differing patterns of genetic association in two clin-
ically distinct subsets of psoriasis. In guttate psoriasis,
evidence of allelic association for PSORS1 appears at least
as prominent as that seen in PV. In contrast, palmoplantar
pustular psoriasis (PPP) shows no evidence of PSORS1
association (Asumalahti et al, 2003).
PV has been subclassified according to age of onset.
Early-onset psoriasis (also referred to as type 1) has onset
before the age of 40 y, with peak onset at 16–22 y of age
and comprises 70% of all psoriatics. Late-onset psoriasis
(LOP), also termed type II psoriasis, shows onset at or after
age 40 y with a peak age of onset between 57 and 60 y
(Henseler and Christophers, 1985). Although these forms
of psoriasis cannot be distinguished on clinical or histo-
pathological grounds, however, a distinct pattern of HLA
association has been reported. Hence, with early-onset
psoriasis, which also displays a strong family history, strong
association with Class 1 HLA alleles and specifically HLA-
Cw6 is observed. In contrast, LOP is rarely familial and
typically demonstrates an increased frequency of HLA-Cw2
and HLA-B27 (Henseler, 1997). Clinically, early-onset pso-
riasis is found to be more extensive, is frequently recurrent,
and more frequently associated with involvement of nail.
A single nucleotide polymorphism (SNP) at position
þ 1243 of the CDSN gene showed the strongest evidence
of association in patients with a very early age of onset
(0–20 y). The strength of association decreased in patients
with an increased age of onset (21–39 y) and in late-onset
patients (i.e., 440 y) the association between CDSN and1Contributed equally to this study.
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psoriasis was barely significant (Tazi et al, 1999). The same
study also showed a diminished, although still a highly sig-
nificant association with HLA-Cw6, across all three of these
age of onset groups.
In this work, we have investigated the role of specific
PSORS1 susceptibility alleles in LOP. We genotyped pa-
tients and controls for the markers described in previous
mapping studies, in order to provide a comprehensive as-
sessment of PSORS1 candidate genes in psoriasis sus-
ceptibility and to further our understanding of the etiology of
the disease in LOP.
Results
A comparison of allele frequencies between all late onset
subjects with chronic plaque psoriasis and controls re-
vealed a statistically significant increase in allele frequency
for HLA-Cw0602 (p¼0.037), CDSN5 (p¼0.041),
HCRWC (p¼0.013), and HCR SNP þ 325T (p¼0.038) in
the total late-onset patient group (Table S1). Carriage fre-
quencies (Table S2), in which the presence or absence of an
allele is scored per individual, demonstrated that all alleles
previously identified to be associated with type I psoriasis
are increased in the late-onset patient group compared with
controls; however, only HLA-C and HCR alleles were sig-
nificantly increased. Thus, of the late-onset group (age of
onsetX40 y old), 30.3% (n¼ 44) carried the HLA-Cw0602
allele compared with 15.5% (n¼47) in the controls
(p¼ 2  104) (Table S2). HCRWC showed a significant
increase (p¼0.016) in carrier frequency of 52% in the late-
onset subjects compared with 39.1% in controls (Table S2).
Also, HCR SNP þ2327G showed a significant increase in
carrier frequency, with 54.8% in controls compared with
66% in patients (p¼0.027).
To further examine the role of age of onset, the patient
group was stratified for subjects presenting at or after the
age of 50 y old. In this stratified group, no significant dif-
ferences were observed for allele frequencies between cas-
es and controls for any of the genes studied (Table S1). In an
analysis of allele carriage frequencies, comparing cases
and controls only the haplotype of the HCR SNP, i.e.,
HCRWC, produced a significant change. Thus HCRWC
was increased (54.5%, p¼ 0.034) in the X50 y age group,
compared with a carriage frequency of 39.1% in the control
group (Table S2); however, with correction for multiple test-
ing this was also not significant.
Discussion
Psoriasis linkage and association studies have identified a
major psoriasis susceptibility locus for psoriasis on chro-
mosome 6p21.3 (PSORS1) within the MHC (Nair et al, 1997;
Trembath et al, 1997). Within this locus, there are three main
candidate genes for psoriasis susceptibility, HLA-C, CDSN,
and HCR. One hundred and forty-five patients with psoria-
sis presenting in later life and 309 normal control individuals
were genotyped for 22 HLA-C alleles and a total of 7 SNPs
from CDSN and HCR genes. These markers have previously
demonstrated a significant association with psoriasis (Ca-
pon et al, 2002). Our analysis reveals evidence of only a
weak association for HLA-Cw6, CDSN5, HCRWC, and
HCR SNP þ325T in the late-onset group taken as a whole.
Carriage frequencies for these alleles were also increased in
the patient group compared with controls and although
these results reach statistical significance, odds ratios sug-
gest that this association is several orders of magnitude less
than observed in classical early-onset disease. The age
ranges for late- and early-onset psoriasis represent two
overlapping normal distributions (Christophers and Hens-
eler, 1989). Thus, it is possible that the weak association
observed for PSORS1 alleles in this cohort of late-onset
patients may result from a number of type I psoriasis pa-
tients within the area of overlap of the two normal distribu-
tions. To examine this, we analyzed data for patients with an
increased age of onset for psoriasis, namely 50 y and
above. With this stratification, no evidence was found,
based on examination of allele frequencies, for allelic as-
sociation with the alleles at the PSORS1 locus. Analysis of
allele carrier frequencies followed a similar pattern; howev-
er, a small non-significant increase was observed for
HCRWC. Thus, these findings suggest diminished associ-
ation with PSORS1 alleles with increasing age of onset for
psoriasis. The patient group was also stratified based on
family history of psoriasis (data not shown); however, as-
sociation with HLA-C was observed in both those with and
without a family history of psoriasis. This suggests separa-
tion on the basis of family history of psoriasis is not an
effective means of screening out individuals from the region
overlapping with the normal distribution of early-onset pso-
riasis. Thus preliminary analysis suggests stratification by
age of onset appears to be a more effective means of iden-
tifying patients with PSORS1-associated psoriasis who
develop disease after the age of 40 y.
These results may help to further define the role of
PSORS1 in psoriasis susceptibility and in turn assist in cat-
egorizing the various subtypes of the disease. For example
guttate psoriasis, which typically has an age of onset in
adolescence or young adulthood, shows strong association
with PSORS1, identical to that observed in familial psoria-
sis. In contrast, PPP, like LOP, shows no association with
PSORS1 (Asumalahti et al, 2003).
Classically, age of onset before or after 40 y of age has
been used as a convenient means of classification of early-
onset psoriasis and LOP (Christophers and Henseler, 1989).
Our findings provide compelling evidence that early-onset
psoriasis and LOP do not show the same association with
PSORS1 and therefore are genetically distinct subsets of
the disorder. Furthermore, these discussions confirm the
earlier finding in type I and II psoriasis (Henseler and Christ-
ophers, 1985) of an overlap in the age of onset of psoriasis,
between age of onset at 40 y and age of onset at 50 y
of age.
A more instructive way to discriminate type I and II pso-
riasis may be to separate them according to their associ-
ation with PSORS1. Such distinction may inform future
genetic studies of psoriasis subtypes. This might prove in-
formative in assessing future patient treatment, in the
design of clinical trials, and as an exclusion criterion in fu-
ture studies of the etiology of LOP. No studies of other
psoriasis susceptibility loci (PSORS 2–9) have yet been
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undertaken in relation to LOP. Thus, it is possible that a
genetic contribution from one or more of these loci may be
relevant in LOP and hence future studies of these regions
may prove helpful in characterizing any genetic component
of LOP.
Materials and Methods
Patients and controls Ethical approval was given by the medical
ethics committee of St Thomas’s Hospital and informed written
consent was obtained from all participating subjects. All studies
were performed in accordance with the requirements of the
Helsinki Declaration. All patients had a diagnosis of chronic plaque
psoriasis, confirmed by a trained dermatologist, using standard
clinical criteria (Camp, 1998). Patients were categorized as having
LOP if the disease occurred at age 40 y old or older (Table I).
Recruitment was via dermatology clinics at three UK regional cen-
ters namely London (n¼ 61), Glasgow (n¼ 48), and Manchester
(n¼ 36) (total n¼ 145). All patients were of Northern European or-
igin. DNA was extracted from peripheral venous blood samples by
standard methods (Young et al, 2003). In addition, DNA samples
(n¼ 309) from ethnically matched controls were obtained from two
UK populations, namely volunteers recruited from hospital staff of
Guys and St Thomas’ Hospitals, London UK (n¼ 165) and DNA
samples from individuals contributing to the DNA bank of the Tis-
sue Typing laboratory, Guys Hospital, UK (n¼ 144). The same
group of normal control individuals was used previously to dem-
onstrate positive association in an early-onset psoriasis patient
cohort (Asumalahti et al, 2003).
Genotyping The patient and control cohorts were genotyped by a
polymerase chain reaction sequence-specific primer (PCR-SSP)
method for 22 common HLA-C alleles (Bunce et al, 1995). Individ-
uals were also genotyped for CDSN SNPs at þ 619, þ 1240, and
þ 1243 using a PCR-SSP-based assay, which identified eight dis-
tinct alleles of CDSN based on in cis genotyping at these three
positions (Allen et al, 1999). In addition, CDSN SNPs þ 1215 and
þ 1236 were assayed by the ‘‘Taqman’’-Sequence Detection Sys-
tem (PE Applied Biosystems, Warrington, UK). Genotyping for HCR
SNPs þ 325 (þ 269) and þ 2327 (þ 2271) was performed using
a radioactive oligonucleotide hybridization assay (Jeffreys et al,
2000). The high-risk psoriasis HCR allele for psoriasis susceptibil-
ity, HCRWWCC, is defined by four SNPs þ 307T, þ 325T,
þ 1723T, and þ 2327G (Asumalahti et al, 2002). We genotyped
two of these SNPs (þ 325 and þ 2327), which identify the majority
of HCRWWCC alleles (Veal et al, 2002).
Statistical analysis A case–control comparison was made of
allele frequencies and allele carriage frequencies for each SNP.
Statistical comparison of all patients and control individuals was
made using the w2 test and by calculation of odds ratios derived
from allele carriage frequencies. Patients with age of onset for
psoriasis of X50 y of age were also analyzed as a subset, as
above.
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